February 7, 2023
NDTV News


Niclosamide has been extensively used up to now for remedy of tapeworm an infection (Representational)

New Delhi:

The Drugs Controller General of India (DCGI) has given approval to the CSIR and Laxai Life Sciences Private Limited to conduct scientific trial of Colchicine on COVID-19 sufferers, based on an announcement on Saturday.

Ram Vishwakarma, the advisor to the CSIR Director General, mentioned Colchicine together with customary care might be an vital therapeutic intervention for COVID-19 sufferers with cardiac co-morbidities and likewise for lowering pro-inflammatory cytokines, resulting in sooner restoration.

Plenty of world research have confirmed that cardiac issues throughout course of COVID-19 infections and post-Covid syndrome are resulting in lack of many lives, and it’s important to search for new or repurposed medication, he mentioned.

“Council of Scientific & Industrial Research (CSIR), and Laxai Life Sciences Pvt Ltd Hyderabad, have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 patients,” the assertion mentioned.

The accomplice CSIR institutes on this vital scientific trial are the CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad and CSIR-Indian Institute of Integrative Medicine (IIIM), Jammu.

India is likely one of the largest producers of this key drug and if profitable, it will likely be made out there to sufferers at an inexpensive value, IICT Director S Chandrasekhar mentioned.

Laxai Life Sciences CEO Ram Upadhayay mentioned the enrolment of sufferers has already begun at a number of websites throughout India and the trial is prone to be accomplished within the subsequent 8-10 weeks.

He additional added that this drug might be made out there to a big inhabitants of India based mostly on the outcomes of this trial and regulatory approval.

Last week, the CSIR introduced that it together with Laxai Life Sciences Pvt Ltd has initiated part II scientific trials of anti-helminitic drug Niclosamide for remedy of COVID-19.

Niclosamide has been extensively used up to now for remedy of tapeworm an infection in adults in addition to kids. The security profile of this drug has been examined over time and has been discovered protected for human consumption at totally different dose ranges, the CSIR mentioned.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *